Acadia Pharmaceuticals (ACAD) Receivables - Other: 2013-2025
Historic Receivables - Other for Acadia Pharmaceuticals (ACAD) over the last 12 years, with Sep 2025 value amounting to $23.6 million.
- Acadia Pharmaceuticals' Receivables - Other rose 94.08% to $23.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.6 million, marking a year-over-year increase of 94.08%. This contributed to the annual value of $6.0 million for FY2024, which is 45.87% up from last year.
- Acadia Pharmaceuticals' Receivables - Other amounted to $23.6 million in Q3 2025, which was up 93.65% from $12.2 million recorded in Q2 2025.
- Acadia Pharmaceuticals' Receivables - Other's 5-year high stood at $23.6 million during Q3 2025, with a 5-year trough of $403,000 in Q3 2022.
- For the 3-year period, Acadia Pharmaceuticals' Receivables - Other averaged around $7.9 million, with its median value being $6.0 million (2024).
- Its Receivables - Other has fluctuated over the past 5 years, first crashed by 80.99% in 2021, then spiked by 602.54% in 2024.
- Acadia Pharmaceuticals' Receivables - Other (Quarterly) stood at $978,000 in 2021, then dropped by 9.51% to $885,000 in 2022, then spiked by 361.36% to $4.1 million in 2023, then surged by 45.87% to $6.0 million in 2024, then spiked by 94.08% to $23.6 million in 2025.
- Its Receivables - Other stands at $23.6 million for Q3 2025, versus $12.2 million for Q2 2025 and $8.0 million for Q1 2025.